Company Interview / Orthocell expands into global bone substitution market

Key Points:

Orthocell (ASX:OCC) secures strategic rights to Marine Biomedical’s PearlBone technology Marine Biomedical’s FDA application seen as critical for short-term growth Integration aims to position Orthocell as a trauma “one-stop shop” for bone, nerve, and tendon repair Seven consecutive quarters of record revenue reported, with ongoing optimism for share price realignment

Orthocell (ASX:OCC) has solidified its position in the field of regenerative medicine after finalising a strategic investment in Marine Biomedical, granting the company exclusive rights to the innovative PearlBone technology. John Van Der Wielen spotlights the significance of this partnership, pointing to the shared scientific foundation between both companies through Professor Minghao Zhang from the University of Western Australia. Marine Biomedical has developed a unique bone regeneration product sourced sustainably from discarded pearl shells from Willie Creek Pearls in the Kimberley, representing a sustainable leap in orthopaedic solutions.

Van Der Wielen highlights the complementary nature of Marine Biomedical’s PearlBone treatment with Orthocell’s own collagen implant, Remplir, currently approved in nine countries for trauma repair involving bone, nerve, and tendon regeneration. The timing of Orthocell’s investment aligns with Marine Biomedical’s imminent FDA application, which is expected to unlock significant value for shareholders. Integration of these products, according to Van Der Wielen, positions Orthocell to become a comprehensive provider within the US$1.6 billion global bone substitution market.

Despite achieving a seventh consecutive quarter of record revenue and maintaining a healthy balance sheet, Van Der Wielen observes a disconnect between the company's operational performance and its share price. He remains optimistic that sustained revenue growth, driven by expanded product offerings and a $50 million cash reserve, will eventually be reflected in Orthocell’s valuation.